China NMPA Medical Device/IVD Registration Services
Navigating China NMPA medical device and IVD registration requires a detailed understanding of classification rules, clinical evidence expectations, submission requirements, and post-market obligations. Cisema provides a full suite of services to ensure accurate classification, compliant documentation, and an efficient registration pathway for all device types.
Comprehensive Support for China NMPA Medical Device and IVD Registration
Cisema provides a comprehensive range of services for companies seeking China NMPA medical device and IVD approval, helping identify the most appropriate and efficient regulatory pathway for each product. To simplify the NMPA registration process and ensure full compliance with Chinese regulatory requirements, we offer the following services:
Clinical Trial
Services
While some medical devices may require clinical trials in China, Cisema specializes in bypassing this step whenever possible. If clinical trials are necessary, we manage the entire process—defining trial criteria, selecting accredited labs, and ensuring full compliance with local regulations.
NMPA Legal
Agent Services
As your official legal representative, Cisema acts as your trusted point of contact with NMPA. Our team ensures all documentation, communications, and regulatory obligations are managed correctly, reducing the risk of errors or delays in the approval process.
Hong Kong Medical
Device Listing
In addition to NMPA registration, Cisema also offers support for registering medical devices in Hong Kong. The registration process in Hong Kong is separate but complementary to NMPA, and we can help you navigate both for a smoother market entry in the region.
Key components of our service offering include:
- Complimentary full-cost calculation including timeline for NMPA registration
- Classification (risk class I, II or III) of medical devices and IVDs
- Clinical pathway strategy
- Advice on applicable legislation and relevant regulations
- Templates and document checklists for application
- Writing of product technical requirements (PTR)
- Test sample import and logistics
- Coordination of type tests
- Translation of documents into Chinese
- Chinese label drafting according to NMPA requirements
- Clinical Evaluation Report (CER) composition
- NMPA application dossier compilation
- Responding to supplementary notice and meetings with NMPA reviewers
- Collection and handover of NMPA certificate
- Clinical Research Organization (CRO) services
- NMPA Legal Agent service for registration and post market surveillance (PMS)
- Post-approval support, e.g. changes, extensions, and renewals of product registrations
Our Expertise in China Medical Device Registration
With over 20 years of experience in medical device registration and regulatory services, Cisema has been helping companies—from innovative life science startups to multinational healthcare giants—navigate complex regulatory landscapes since 2002.
Our team has successfully completed over 5,000 life science projects, including China NMPA registrations, and we understand the nuances of the regulatory process like no one else.
Client Testimonials
China NMPA Registration Process: Simplified
Our consultants guide you through every step of the complex China NMPA registration proces, from determining product classification and preparing Chinese application documents to securing approval and the NMPA certificate. With deep expertise in China’s clinical requirements, Cisema helps companies bypass clinical trials whenever possible; when trials are required, we define the appropriate criteria, coordinate with accredited laboratories, and ensure full regulatory compliance.
Product Classification
China’s medical device registration is divided into three classes: I, II, and III, based on risk. The classification directly impacts the testing and approval requirements for your product.
Regulatory Documentation & Submission
We help prepare your application documents in compliance with Chinese standards, ensuring all required materials are accurately translated and submitted.
Review & Evaluation
Once submitted, NMPA will conduct a review. This can include technical evaluations and—depending on your product—clinical trials. We ensure your application is thorough to avoid delays.
Approval & NMPA Certification
After successful review, your product will receive NMPA certification. This certification is valid for 5 years and ensures that your product can legally be marketed in China.
We highly recommend companies begin engaging with us from the start of the application process as we believe that gross errors can be avoided. Even correctable mistakes will lead to significant and costly delays.
FAQs about China NMPA Medical Device Registration
The China NMPA registration process could be challenging, and can take from a few months to several years, depending on the product. The costs and the exact timeframe of the registration process varies, among all, on its classification and the testing required. REQUEST A NONCOMMITTAL QUOTATION. Medical devices are divided into Class I, II, and III. This system is similar to that in the EU or US and is based on potential risk levels; however, especially in class II there could be variances.
The China NMPA registration process could be challenging, and can take from a few months to several years, depending on the product. The costs and the exact timeframe of the registration process varies, among all, on its classification and the testing required. REQUEST A NONCOMMITTAL QUOTATION. Medical devices are divided into Class I, II, and III. This system is similar to that in the EU or US and is based on potential risk levels; however, especially in class II there could be variances.
The process of China NMPA registration is complex. Even experienced companies could encounter unforeseen challenges. Our committed consultants can guide you through China’s regulatory processes, from identifying product classifications and preparing the application documents in Chinese to approval and issue of the NMPA certificate. Cisema specializes in bypassing clinical trials in China. If clinical trials are mandated, Cisema can define the clinical trial criteria for your product, identify and coordinate with accredited laboratories, and ensure compliance with all regulations. The NMPA approval for medical devices is valid for 5 years. Learn more about the process of China NMPA registration including timeline and how Cisema avoids clinical trials in our brochures.
The NMPA Legal Agent for Medical Devices has a wide range of responsibilities. The agent is not only responsible for the registration, supervision of the tests conducted and administrative component during the registration application, but also bears the joint responsibility for product quality and after-sales business together with the manufacturer. In our service offer for medical device NMPA Legal Agent you will find more information.
Manufacturers intend to appoint a Chinese distributor as NMPA Legal Agent should be aware of the underlying risks involved. Unfortunately, if your distributor is uncooperating at points of your partnership and declines to relinquish the original NMPA certificates and “Technical Requirements” to you, you are in a position of dependency that prevents you from changing distributors, requesting a change or renewal of your NMPA registration and, consequently, importing your products. The only solution in most cases is to change NMPA Legal Agent. If you have problems with your NMPA Legal Agent, we are here to help. What else you should consider when choosing the NMPA Legal Agent, you can learn in our brochures .
- Determining whether your medical device or IVD is correctly classified under China NMPA rules — especially if its classification has recently changed.
- Understanding the total time, cost, and testing requirements involved in the China NMPA registration process.
- Complying with China’s quality management system expectations and aligning your existing QMS with NMPA standards.
- Managing situations where a distributor has acted as your NMPA Legal Agent but is no longer cooperative or aligned with your business needs.
- Identifying how many type tests, performance tests, and test samples are required for your product category.
- Assessing whether clinical evidence or a clinical trial will be required before market approval can be granted.
- Protecting sensitive manufacturing information, formulations, or proprietary methods during the registration process.
- Determining whether your medical device qualifies for China’s prioritized or expedited registration pathways.
With more than 20 years of on-the-ground expertise, Cisema helps companies navigate these hurdles with clarity and confidence — and achieve successful NMPA registrations.
The timeline for NMPA registration can vary greatly depending on factors like product classification, the complexity of your device, and whether clinical trials are required. Generally, it takes anywhere from 6 months to 2 years for Class I and II devices, while Class III devices may take even longer due to more stringent requirements.
However, with Cisema’s support, we can significantly streamline the process by providing expert guidance and anticipating challenges ahead of time. We’ll work with you to establish a clear timeline, factoring in all potential delays, and ensure that your product is ready for market as quickly as possible.
As part of the NMPA registration process, a legal agent is required to act as your official representative in China. This is a mandatory role that facilitates communication between your company and the NMPA.
At Cisema, we offer NMPA Legal Agent Services, ensuring that all documentation, regulatory filings, and official communications are handled in compliance with local laws and regulations. By acting as your legal representative, we help ensure that your submission goes smoothly, minimizing the risk of delays or rejection.
Yes, in addition to China NMPA registration, Cisema also offers support for Hong Kong medical device listing. Our consultants are well-versed in the regulatory landscapes of different regions, and we can help you navigate the approval processes in both China and Hong Kong, ensuring smooth entry into these important markets.
With Cisema’s Hong Kong Medical Device Listing Service, we simplify the process for you, providing the same high level of expertise and support that we do for NMPA registrations.
China’s medical device registration process is divided into three classes based on risk:
- Class I: Low risk. These devices have the least regulatory requirements and may be approved faster.
- Class II: Moderate risk. These devices require more testing and documentation, and some may require clinical trials.
- Class III: High risk. These devices require extensive clinical testing and a more comprehensive evaluation process.
Cisema’s expertise in product classification ensures that your device is accurately categorized, which helps determine the registration pathway and necessary tests. We guide you through this critical step to avoid errors that could delay approval.
The cost of NMPA registration can vary based on multiple factors, including product classification, whether clinical trials are required, and the complexity of the registration process. Some devices may also require additional testing, which adds to the cost.
At Cisema, we offer tailored quotations based on the specifics of your product and regulatory needs. Request a noncommittal quotation to get a clearer idea of the cost based on your device’s classification and testing requirements.
Remember, an upfront investment in professional consultation and support can often save you from costly delays and mistakes later.
Clinical trials are required for some medical devices in China, particularly for Class II and III devices. However, Cisema has a track record of bypassing clinical trials when possible, helping you save time and resources.
If clinical trials are necessary, our team can help define the clinical trial criteria, coordinate with accredited laboratories, and ensure full compliance with NMPA regulations. With Cisema’s Clinical Trial Services, we’ll manage the process from start to finish, ensuring that all testing is done in the right laboratories and in line with NMPA’s requirements.
One of the challenges many companies face when dealing with the NMPA registration process is language barriers. At Cisema, we provide support in multiple languages, including Korean, English, Japanese, German, French, Italian, and Spanish.
Our multilingual consultants help bridge communication gaps, ensuring that your application documents are accurately translated, and your interactions with local authorities are smooth and effective. This comprehensive language support significantly reduces the risk of misunderstandings and ensures that your registration process stays on track.
Get In Touch
Need guidance or a quote for medical device, IVD, or SaMD registration in China or Southeast Asia?
Cisema’s experts are ready to support your next market expansion.
China NMPA Medical Device/IVD Regulatory News
Gain clear insight into the regulatory shifts in medical devices, IVDs, and pharmaceuticals that are shaping market access in China and Southeast Asia.
